TBPH logo

Theravance Biopharma (TBPH) EBITDA

Annual EBITDA

-$42.07 M
+$595.00 K+1.39%

December 1, 2024


Summary


Performance

TBPH EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTBPHprofitabilitymetrics:

Quarterly EBITDA

-$8.30 M
+$362.00 K+4.18%

December 1, 2024


Summary


Performance

TBPH Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTBPHprofitabilitymetrics:

TTM EBITDA

-$39.15 M
-$5.32 M-15.73%

December 1, 2024


Summary


Performance

TBPH TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherTBPHprofitabilitymetrics:

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

TBPH EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+1.4%0.0%0.0%
3 y3 years+83.0%0.0%0.0%
5 y5 years+79.3%0.0%0.0%

TBPH EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+83.0%-178.8%+84.8%-29.2%+81.3%
5 y5-yearat high+85.4%-178.8%+92.3%-29.2%+86.4%
alltimeall time-565.2%+85.4%-178.8%+92.3%-29.2%+86.4%

Theravance Biopharma EBITDA History

DateAnnualQuarterlyTTM
Dec 2024
-$42.07 M(-1.4%)
-$8.30 M(-4.2%)
-$39.15 M(+15.7%)
Sep 2024
-
-$8.66 M(-36.3%)
-$33.83 M(+8.4%)
Jun 2024
-
-$13.60 M(+58.2%)
-$31.20 M(+3.0%)
Mar 2024
-
-$8.59 M(+188.8%)
-$30.30 M(-29.0%)
Dec 2023
-$42.66 M(-46.3%)
-$2.98 M(-50.7%)
-$42.66 M(-17.0%)
Sep 2023
-
-$6.04 M(-52.4%)
-$51.37 M(-11.5%)
Jun 2023
-
-$12.70 M(-39.4%)
-$58.05 M(-9.4%)
Mar 2023
-
-$20.95 M(+79.3%)
-$64.10 M(-18.9%)
Dec 2022
-$79.42 M(-68.0%)
-$11.68 M(-8.1%)
-$79.05 M(-35.2%)
Sep 2022
-
-$12.71 M(-32.2%)
-$121.91 M(-23.9%)
Jun 2022
-
-$18.75 M(-47.8%)
-$160.21 M(-11.0%)
Mar 2022
-
-$35.90 M(-34.2%)
-$180.05 M(-13.9%)
Dec 2021
-$248.08 M(-13.8%)
-$54.55 M(+6.9%)
-$209.20 M(-20.4%)
Sep 2021
-
-$51.01 M(+32.2%)
-$262.66 M(-3.3%)
Jun 2021
-
-$38.60 M(-40.7%)
-$271.65 M(-3.8%)
Mar 2021
-
-$65.05 M(-39.8%)
-$282.26 M(-1.9%)
Dec 2020
-$287.82 M(+41.4%)
-$108.01 M(+80.0%)
-$287.82 M(+21.8%)
Sep 2020
-
-$59.99 M(+21.9%)
-$236.23 M(+2.6%)
Jun 2020
-
-$49.20 M(-30.3%)
-$230.23 M(+9.0%)
Mar 2020
-
-$70.62 M(+25.2%)
-$211.25 M(+3.8%)
Dec 2019
-$203.60 M(-4.2%)
-$56.41 M(+4.5%)
-$203.60 M(+4.0%)
Sep 2019
-
-$54.00 M(+78.7%)
-$195.70 M(-1.7%)
Jun 2019
-
-$30.22 M(-52.0%)
-$199.04 M(-6.8%)
Mar 2019
-
-$62.97 M(+29.8%)
-$213.50 M(+0.5%)
DateAnnualQuarterlyTTM
Dec 2018
-$212.44 M(-18.0%)
-$48.51 M(-15.4%)
-$212.44 M(-11.7%)
Sep 2018
-
-$57.34 M(+28.3%)
-$240.70 M(-2.3%)
Jun 2018
-
-$44.68 M(-27.8%)
-$246.29 M(-6.8%)
Mar 2018
-
-$61.91 M(-19.4%)
-$264.33 M(+2.0%)
Dec 2017
-$259.14 M(+47.2%)
-$76.78 M(+22.0%)
-$259.14 M(+8.6%)
Sep 2017
-
-$62.92 M(+0.3%)
-$238.54 M(+14.7%)
Jun 2017
-
-$62.72 M(+10.6%)
-$207.98 M(+8.3%)
Mar 2017
-
-$56.72 M(+0.9%)
-$192.00 M(+9.1%)
Dec 2016
-$176.04 M(-1.3%)
-$56.19 M(+73.6%)
-$176.04 M(+1.0%)
Sep 2016
-
-$32.36 M(-30.8%)
-$174.30 M(-5.4%)
Jun 2016
-
-$46.73 M(+14.7%)
-$184.31 M(+1.2%)
Mar 2016
-
-$40.76 M(-25.1%)
-$182.12 M(+2.2%)
Dec 2015
-$178.28 M(-21.6%)
-$54.45 M(+28.5%)
-$178.28 M(-4.6%)
Sep 2015
-
-$42.38 M(-4.9%)
-$186.94 M(-3.4%)
Jun 2015
-
-$44.55 M(+20.7%)
-$193.55 M(-5.6%)
Mar 2015
-
-$36.91 M(-41.5%)
-$205.03 M(-9.8%)
Dec 2014
-$227.40 M(+48.0%)
-$63.11 M(+28.8%)
-$227.40 M(+9.5%)
Sep 2014
-
-$48.99 M(-12.6%)
-$207.68 M(+4.2%)
Jun 2014
-
-$56.02 M(-5.5%)
-$199.21 M(+9.8%)
Mar 2014
-
-$59.29 M(+36.6%)
-$181.45 M(+18.1%)
Dec 2013
-$153.63 M(+2329.3%)
-$43.39 M(+7.1%)
-$153.63 M(+39.4%)
Sep 2013
-
-$40.52 M(+5.9%)
-$110.25 M(+58.1%)
Jun 2013
-
-$38.25 M(+21.5%)
-$69.72 M(+121.5%)
Mar 2013
-
-$31.47 M
-$31.47 M
Dec 2012
-$6.32 M
-
-

FAQ

  • What is Theravance Biopharma annual EBITDA?
  • What is the all time high annual EBITDA for Theravance Biopharma?
  • What is Theravance Biopharma annual EBITDA year-on-year change?
  • What is Theravance Biopharma quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Theravance Biopharma?
  • What is Theravance Biopharma quarterly EBITDA year-on-year change?
  • What is Theravance Biopharma TTM EBITDA?
  • What is the all time high TTM EBITDA for Theravance Biopharma?
  • What is Theravance Biopharma TTM EBITDA year-on-year change?

What is Theravance Biopharma annual EBITDA?

The current annual EBITDA of TBPH is -$42.07 M

What is the all time high annual EBITDA for Theravance Biopharma?

Theravance Biopharma all-time high annual EBITDA is -$6.32 M

What is Theravance Biopharma annual EBITDA year-on-year change?

Over the past year, TBPH annual EBITDA has changed by +$595.00 K (+1.39%)

What is Theravance Biopharma quarterly EBITDA?

The current quarterly EBITDA of TBPH is -$8.30 M

What is the all time high quarterly EBITDA for Theravance Biopharma?

Theravance Biopharma all-time high quarterly EBITDA is -$2.98 M

What is Theravance Biopharma quarterly EBITDA year-on-year change?

Over the past year, TBPH quarterly EBITDA has changed by $0.00 (0.00%)

What is Theravance Biopharma TTM EBITDA?

The current TTM EBITDA of TBPH is -$39.15 M

What is the all time high TTM EBITDA for Theravance Biopharma?

Theravance Biopharma all-time high TTM EBITDA is -$30.30 M

What is Theravance Biopharma TTM EBITDA year-on-year change?

Over the past year, TBPH TTM EBITDA has changed by $0.00 (0.00%)